MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Thermo Fisher Scientific Total Assets 2011-2026 | TMO
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110 B | 97.3 B | 98.7 B | 97.2 B | 95.1 B | 69.1 B | 58.4 B | 56.2 B | 56.7 B | 45.9 B | 40.9 B | 42.9 B | 31.9 B | 27.4 B | 26.8 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 B | 26.8 B | 63.7 B |
Quarterly Total Assets Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 103 B | 101 B | 99 B | 100 B | 98.5 B | 97.1 B | 97.1 B | 94.1 B | 94.7 B | 97.2 B | 90.5 B | - | 92.7 B | 95.1 B | 73.6 B | 67.7 B | 65.9 B | 69.1 B | 69.1 B | 69.1 B | 69.1 B | 58.4 B | 58.4 B | 58.4 B | 58.4 B | 56.2 B | 56.2 B | 56.2 B | 56.2 B | 56.7 B | 56.7 B | 56.7 B | 56.7 B | 45.9 B | 45.9 B | 45.9 B | 45.9 B | 40.8 B | 40.8 B | 40.8 B | 40.8 B | 42.9 B | 42.9 B | 42.9 B | 42.9 B | 31.9 B | 31.9 B | 31.9 B | 31.9 B | 27.4 B | 27.4 B | 27.4 B | 27.4 B | 26.8 B | 26.8 B | 26.8 B | 26.8 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 103 B | 26.8 B | 58.8 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
684 M | $ 8.9 | 0.39 % | $ 593 M |  USA |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 13.85 | 1.47 % | $ 99.4 M |  Israel |
 |
Castle Biosciences
CSTL
|
531 M | $ 26.04 | 0.81 % | $ 723 M | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
6.34 B | $ 68.33 | 2.99 % | $ 26.7 B | USA |
 |
Guardant Health
GH
|
2.01 B | $ 87.63 | 0.52 % | $ 11 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 154.73 | 1.82 % | $ 7.67 B | USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 17.59 | 1.56 % | $ 937 M | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
IQVIA Holdings
IQV
|
29.9 B | $ 168.86 | 2.41 % | $ 29 B | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | $ 103.89 | 0.04 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 15.62 | 4.45 % | $ 472 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 16.88 | -2.37 % | $ 2.19 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 100.35 | 2.81 % | $ 8.28 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 2.9 | 2.11 % | $ 94.1 K | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 195.77 | 2.29 % | $ 140 B | USA |
 |
NeoGenomics
NEO
|
1.36 B | $ 8.36 | 1.46 % | $ 1.07 B | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.4 | 2.95 % | $ 420 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 121.89 | 2.18 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.82 | -0.06 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
5.69 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
10.7 B | $ 113.9 | 1.85 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.12 | 0.9 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 9.28 | 10.24 % | $ 263 M | Israel |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 9.32 | 2.25 % | $ 2.02 B | USA |
 |
Lantheus Holdings
LNTH
|
2.23 B | $ 78.96 | 0.59 % | $ 5.33 B | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 452.34 | -0.29 % | $ 13 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
3.71 B | $ 1 219.76 | 1.76 % | $ 25.1 B |  Schweiz |
 |
Celcuity
CELC
|
245 M | $ 114.23 | -0.58 % | $ 4.51 B | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Twist Bioscience Corporation
TWST
|
642 M | $ 46.61 | 3.55 % | $ 2.79 B | USA |
 |
National Research Corporation
NRC
|
135 M | $ 18.05 | 3.71 % | $ 404 M | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
1.39 B | $ 199.84 | 1.09 % | $ 19.7 B | USA |